Researchers have significantly advanced this progress of an novel treatment for amyloid heart disease, utilizing the compound. Early trial results indicates significant outcomes for patients diagnosed by a severe condition. The focus represents BridgeBio's commitment to addressing significant healthcare needs in a cardiology arena. Attruby: Bridge